MRI引导经尿道超声消融前列腺后的12个月前列腺体积缩小
在TULSA I期临床试验的中心影像学回顾中,29例局限性前列腺癌患者完成治疗当天及12个月MRI和活检复查;12个月有活力前列腺体积中位缩小88%,与基于240 CEM43热剂量的延迟热消融体积预测的90%高度一致,而治疗当天无灌注体积仅预测53%缩小,低估了消融范围。
要点
- TULSA术后12个月有活力前列腺体积中位缩小88%,与延迟热消融体积预测的90%高度一致。
- 治疗当天增强MRI无灌注体积仅预测53%缩小,低估了实际12个月有活力组织缩减。
- 无灌注体积仅为急性热消融体积的64%,报告12个月有活力体积缩减的60%(53%而非实际88%)。
核心结论
- 基于TULSA I期MRI和活检数据的定量体积测量显示,240 CEM43热剂量边界的延迟热消融体积是有用的12个月有活力前列腺组织缩减预测指标,而治疗当天无灌注体积低估组织消融。
研究设计与样本
- 已发表机构审查委员会批准的前瞻性多中心单臂I期临床试验的中心影像学回顾,30例中29例有治疗当天及12个月MRI和活检资料可供分析。
关键影像表现/征象
- 治疗当天采用对比增强MRI测量无灌注体积(NPV),12个月随访采用T2加权MRI测量剩余前列腺体积并减去12个月NPV,再按活检核心纤维化比例缩放。
- 基于MR测温的急性热消融体积(ATAV,55°C等温线)和延迟热消融体积(DTAV,43°C下240累积等效分钟热剂量等值线)用于预测体积缩减。
诊断标准与关键数值
- 12个月有活力前列腺体积中位缩减88%,DTAV预测缩减90%。
- 治疗当天NPV仅预测53%体积缩减,并分别低估ATAV和DTAV达36%和51%。
- 治疗当天NPV为急性热消融体积(ATAV)的64%,仅报告12个月有活力前列腺组织缩减的60%(53%而非实际88%)。
临床应用与阅片要点
- 阅片时可将240 CEM43热剂量边界的DTAV作为12个月有活力前列腺组织缩减的预测参考。
- 治疗当天对比增强MRI的NPV会低估组织消融范围,解读术后即刻影像时需注意。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To quantitatively assess 12-month prostate volume (PV) reduction based on T2-weighted MRI and immediate post-treatment contrast-enhanced MRI non-perfused volume (NPV), and to compare measurements with predictions of acute and delayed ablation volumes based on MR-thermometry (MR-t), in a central radiology review of the Phase I clinical trial of MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer.
MATERIALS AND METHODS: Treatment day MRI and 12-month follow-up MRI and biopsy were available for central radiology review in 29 of 30 patients from the published institutional review board-approved, prospective, multi-centre, single-arm Phase I clinical trial of TULSA. Viable PV at 12 months was measured as the remaining PV on T2-weighted MRI, less 12-month NPV, scaled by the fraction of fibrosis in 12-month biopsy cores. Reduction of viable PV was compared to predictions based on the fraction of the prostate covered by the MR-t derived acute thermal ablation volume (ATAV, 55°C isotherm), delayed thermal ablation volume (DTAV, 240 cumulative equivalent minutes at 43°C thermal dose isocontour) and treatment-day NPV. We also report linear and volumetric comparisons between metrics.
RESULTS: After TULSA, the median 12-month reduction in viable PV was 88%. DTAV predicted a reduction of 90%. Treatment day NPV predicted only 53% volume reduction, and underestimated ATAV and DTAV by 36% and 51%.
CONCLUSION: Quantitative volumetry of the TULSA phase I MR and biopsy data identifies DTAV (240 CEM43 thermal dose boundary) as a useful predictor of viable prostate tissue reduction at 12 months. Immediate post-treatment NPV underestimates tissue ablation.
KEY POINTS: • MRI-guided transurethral ultrasound ablation (TULSA) achieved an 88% reduction of viable prostate tissue volume at 12 months, in excellent agreement with expectation from thermal dose calculations. • Non-perfused volume on immediate post-treatment contrast-enhanced MRI represents only 64% of the acute thermal ablation volume (ATAV), and reports only 60% (53% instead of 88% achieved) of the reduction in viable prostate tissue volume at 12 months. • MR-thermometry-based predictions of 12-month prostate volume reduction based on 240 cumulative equivalent minute thermal dose volume are in excellent agreement with reduction in viable prostate tissue volume measured on pre- and 12-month post-treatment T2w-MRI.
引用
- Bonekamp D, Wolf MB, Roethke MC, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol. 2018. PMID: 29943185. doi:10.1007/s00330-018-5584-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。